147 Episoder

  1. Strategies for Treatment Pauses in Neovascular AMD

    Publisert: 2.2.2023
  2. Gene Therapy of Inherited Retinal Diseases

    Publisert: 26.1.2023
  3. Suprachoroidal Tyrosinase Therapy of Neovascular AMD

    Publisert: 12.1.2023
  4. KSI-301 (tarcocimab tedromer) therapy of Retinal Vein Occlusion

    Publisert: 5.1.2023
  5. The Efficacy of Avacincaptad Pegol in Treatment of Geographic Atrophy: Gather 1 & 2 Study Results

    Publisert: 15.12.2022
  6. En Face OCT, Intermediate AMD, and Georgraphic Atrophy

    Publisert: 8.12.2022
  7. Safety of Pegcetacoplan in the 24 month Derby and Oaks Studies

    Publisert: 1.12.2022
  8. Predominantly Peripheral Lesions on Ultra-Wide field Imaging & Risk of DR Worsening Over Time

    Publisert: 17.11.2022
  9. 10 Year Retrospective Review of a PHP Device for Early Detection of Neovascular AMD

    Publisert: 10.11.2022
  10. Current Therapy for Venous Occlusive Disease and a Clinical Trial Involving Stem Cell Therapy for CRVO

    Publisert: 27.10.2022
  11. Senolytic Therapy for Diabetic Macular Edema and Neovascular AMD

    Publisert: 20.10.2022
  12. Assessment of Geographic Atrophy Lesion Progression in the Phase 3 Oaks and Derby Trials

    Publisert: 13.10.2022
  13. The Role of the Clinician in Promoting Innovation

    Publisert: 6.10.2022
  14. The DAVIO Study: 12 Month Results

    Publisert: 22.9.2022
  15. Treat and Extend Therapy of Diabetic Macular Edema

    Publisert: 15.9.2022
  16. Prophylactic IOP Lowering Measures in Anti-VEGF Injections: A Meta-Analysis

    Publisert: 8.9.2022
  17. Real World Efficacy, Durability and Safety of Faricimab

    Publisert: 1.9.2022
  18. New Treatments for Radiation Retinopathy

    Publisert: 25.8.2022
  19. Gene Therapy of Inherited Retinal Diseases

    Publisert: 18.8.2022
  20. RNA Anti Sense Therapy for Geographic Atrophy

    Publisert: 11.8.2022

4 / 8

Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.

Visit the podcast's native language site